A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03219450|
Recruitment Status : Recruiting
First Posted : July 17, 2017
Last Update Posted : May 18, 2021
Dana-Farber Cancer Institute
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Matthew S. Davids, MD, Dana-Farber Cancer Institute
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||March 31, 2023|
|Estimated Study Completion Date :||March 31, 2025|